Argentine researchers are about to complete de development of the ARVAC Cecilia Grierson Covid-19 vaccine, which is why volunteers are needed for the 2/3 trial phase, it was reported in Buenos Aires. The new drug is expected to be cleared by mid-2023.
Argentina s National Agency for the Promotion of Research, Technological Development and Innovation (Agencia I+D+i) granted funding worth AR$ 1.1 billion (around US$ 3.18 million at the unofficial exchange rate) to carry out clinical studies of phases II and III of the ARVAC Cecilia Grierson Covid 19 vaccine, it was reported.